Market Intelligence, Clinical Progress, and High-Purity Reagents for Tumor-Associated Macrophage (TAM) Targeted Therapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CD163 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD163 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View CD163 Products |
| Gene Delivery | CD163 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View CD163 Products |
| Benchmark Ab | Anti-CD163 (Sequence of clinical benchmark) Recombinant positive control. |
View CD163 Products |
| Validator | CD163 siRNA Set For knockdown verification. |
View CD163 Products |
| Related Target A | CSF1R Synergistic macrophage survival and polarization pathway. |
View CSF1R Products |
| Related Target B | CD206 Alternative M2 macrophage marker for dual-targeting or selectivity screening. |
View CD206 Products |
| Related Target C | MARCO Scavenger receptor on immunosuppressive myeloid cells. |
View MARCO Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Soluble CD163 (sCD163) decoy interference | Recombinant sCD163 (truncated ECD) with verified theoretical MW for competitive binding assays |
| Native glycosylation requirements (9 SRCR domains) | HEK293 expression system ensuring native post-translational modifications |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live CD163 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD163 therapeutics is intensifying, with major players shifting focus from traditional mAbs to antibody-drug conjugates (ADCs) and bispecific T-cell engagers. As first-generation therapies targeting tumor-associated macrophages (TAMs) reach the clinic, the next wave of R&D is targeting CD163-mediated internalization for selective payload delivery and TAM reprogramming.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC / Immunotoxin | Macrophage Pharma, Oncology Spin-offs | Solid Tumors (TAM Depletion) | Internalization Assay (Need high-purity ECD-Fc) |
| Bispecific / Engager | Roche, Innovent Biologics | Advanced Solid Tumors | Heterodimer Validation (Need Cross-reactive Abs) |
| Monoclonal Antibody | Halozyme, Boehringer Ingelheim | Fibrosis, Inflammatory Diseases | Blockade Assay (Need native conformation) |